MX2020013924A - Composicion inmunogena para paratuberculosis. - Google Patents

Composicion inmunogena para paratuberculosis.

Info

Publication number
MX2020013924A
MX2020013924A MX2020013924A MX2020013924A MX2020013924A MX 2020013924 A MX2020013924 A MX 2020013924A MX 2020013924 A MX2020013924 A MX 2020013924A MX 2020013924 A MX2020013924 A MX 2020013924A MX 2020013924 A MX2020013924 A MX 2020013924A
Authority
MX
Mexico
Prior art keywords
paratuberculosis
immunogenic composition
map
polypeptide
infection
Prior art date
Application number
MX2020013924A
Other languages
English (en)
Inventor
John Hermon-Taylor
Original Assignee
Hav Vaccines Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hav Vaccines Ltd filed Critical Hav Vaccines Ltd
Publication of MX2020013924A publication Critical patent/MX2020013924A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins

Abstract

Una vacuna que comprende un polipéptido que comprende una secuencia de aminoácidos de por lo menos 9 aminoácidos contiguos de la región N-terminal de P900 de MAP, o un polinucleótido que codifica el polipéptido, para usarse en un método para tratar o prevenir una infección con MAP o una condición o síntoma asociado con la infección con MAP en un sujeto.
MX2020013924A 2018-07-11 2019-07-10 Composicion inmunogena para paratuberculosis. MX2020013924A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1811382.9A GB201811382D0 (en) 2018-07-11 2018-07-11 Vaccine
PCT/GB2019/051933 WO2020012177A1 (en) 2018-07-11 2019-07-10 Immunogenic composition for paratuberculosis

Publications (1)

Publication Number Publication Date
MX2020013924A true MX2020013924A (es) 2021-03-02

Family

ID=63273113

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013924A MX2020013924A (es) 2018-07-11 2019-07-10 Composicion inmunogena para paratuberculosis.

Country Status (14)

Country Link
US (1) US20210338791A1 (es)
EP (1) EP3820507A1 (es)
JP (1) JP2021524485A (es)
KR (1) KR20210033490A (es)
CN (1) CN113329765A (es)
AU (1) AU2019301899A1 (es)
BR (1) BR112021000312A2 (es)
CA (1) CA3105763A1 (es)
GB (1) GB201811382D0 (es)
IL (1) IL280070B2 (es)
MA (1) MA53131A (es)
MX (1) MX2020013924A (es)
SG (1) SG11202100120TA (es)
WO (1) WO2020012177A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700487D0 (en) * 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
WO1990011092A1 (en) 1989-03-21 1990-10-04 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
EP0632722A4 (en) 1992-03-20 1997-07-30 Baylor College Medicine DNA TRANSPORTATION SYSTEM AND INSTRUCTIONS FOR USE.
WO1993019768A1 (en) 1992-04-03 1993-10-14 The Regents Of The University Of California Self-assembling polynucleotide delivery system
US5651981A (en) 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
US5527928A (en) 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
US7074559B2 (en) * 2002-03-06 2006-07-11 Refents of the University of Minnesota Mycobacterial diagnostics
JP5244593B2 (ja) 2005-08-09 2013-07-24 ハブ バクシーンズ リミテッド 免疫原性構築物
EP2948173A1 (en) * 2013-01-28 2015-12-02 Danmarks Tekniske Universitet A single or multistage mycobacterium avium subsp. paratuberculosis subunit vaccine
GB201700487D0 (en) 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic

Also Published As

Publication number Publication date
CA3105763A1 (en) 2020-01-16
AU2019301899A1 (en) 2021-01-14
US20210338791A1 (en) 2021-11-04
GB201811382D0 (en) 2018-08-29
KR20210033490A (ko) 2021-03-26
SG11202100120TA (en) 2021-02-25
CN113329765A (zh) 2021-08-31
EP3820507A1 (en) 2021-05-19
BR112021000312A2 (pt) 2021-04-13
MA53131A (fr) 2021-05-19
WO2020012177A1 (en) 2020-01-16
IL280070B2 (en) 2024-04-01
IL280070A (en) 2021-03-01
JP2021524485A (ja) 2021-09-13
IL280070B1 (en) 2023-12-01

Similar Documents

Publication Publication Date Title
BR112017019625A2 (pt) udp-glicosiltransferases
EA201791426A1 (ru) Полипептид и иммуномодуляция
WO2015107363A3 (en) Mycobacterial antigen composition
MY178365A (en) Vaccine composition against streptococcus suis infection
PH12017501520A1 (en) Fusarium toxin-cleaving polypeptide variants, additives containing same, use of same, and method for splitting fusarium toxins
EA202190240A1 (ru) Варианты рекомбинантного белка
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
BR112017020308A2 (pt) udp-glicosiltransferases
MX2019009551A (es) Enzima lipolitica para usarse en horneado.
PH12017502323A1 (en) Novel xylanase
JP2017052783A5 (es)
NZ721015A (en) Mutant fragments of ospa and methods and uses relating thereto
PE20161406A1 (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas
EP3103471A3 (en) Acinetobacter baumanii antigens and the uses thereof
MX2021001507A (es) Farmaco de diagnostico y metodo de diagnostico para la enfermedad de alzheimer.
MX2020013924A (es) Composicion inmunogena para paratuberculosis.
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
AR101146A1 (es) Proteína con actividad xilanasa
MX2018014966A (es) Peptidos monolipidados resistentes a proteasas.
PH12018500468A1 (en) Fusion protein
MX2018012716A (es) Peptidos bioactivos pegilados y usos de los mismos.
WO2015108856A3 (en) Methods for enhancing the delivery of active agents
PH12020551339A1 (en) MUTANTá-GLUCOSIDASE
MX2017016438A (es) Polipeptido quimerico, vacuna contra la babesiosis, metodos de inmunizacion, metodos de deteccion y kit.
MX2019001555A (es) Secuencia quimerica multiantigenica de aminoacidos para su uso en el diagnostico y como vacuna contra babesia bigemina.